The shift toward chronic disease prevention and improved metabolic health is positioning GLP-1 receptor agonists as a cornerstone of modern obesity treatment strategies Restraint/Challenge Side Effects and High Treatment Costs Pose Adoption Barrier Concerns surrounding the side effects and high cost of GLP-1 receptor agonist therapies pose significant challenges to broader market adoption
A plethora of PASC clinical symptoms and related metabolic impairments indicate involvement of different pathobiological mechanisms such as (i) virus-induced hypoxia/Warburg effect, (ii) iron (Fe)-redox dysregulation (FeRD), (iii) m- Dys and altered bioenergetics, (iv) oxidative stress (OxS) and cellular damage, (v) immuno-pathogenesis and hyperinflammation, (vi) autoimmunity, (vii) dysbiosis, (viii) re-activation of latent pathogens, (ix) persistent viral reservoirs, and (x) viral-hijacked host cellular factors 22,27,137,138
Since animal studies have demonstrated a close link between glutathione and glutamate uptake into both microglia and astrocytes, and NMDA receptor function, we also predicted that glutathione and glutamate levels in the brain would be correlated across all subjects
10.1186/s13023-021-01927-w Orphanet J Rare Dis
Propionyllcarnitine, larginine and niacin in sexual medicine: a nutraceutical approach to erectile dysfunction. Andrologia 44 (2012): 600-604.
31 Clinically, GLP-1 RA use in patients with diabetes is associated with significant primary risk reduction of several obesity-associated cancers
